Page 84 - Read Online

Nickoloff et al. Cancer Drug Resist 2021;4:244-63 I http://dx.doi.org/10.20517/cdr.2020.89 Page 260

necroptosis. Radiat Res 2020;193:435-50.
127. Olivieri G, Bodycote J, Wolff S. Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science
1984;223:594-7.
128. Huang L, Kim PM, Nickoloff JA, Morgan WF. Targeted and non-targeted effects of low-dose ionizing radiation on delayed genomic
instability in human cells. Cancer Res 2007;67:1099-104.
129. Ikushima T. Radio-adaptive response: characterization of a cytogenetic repair induced by low-level ionizing radiation in cultured Chinese
hamster cells. Mutat Res 1989;227:241-6.
130. Rigaud O, Moustacchi E. Radioadaptation for gene mutation and the possible molecular mechanisms of the adaptive response. Mutat Res
1996;358:127-34.
131. Redpath JL, Antoniono RJ. Induction of an adaptive response against spontaneous neoplastic transformation in vitro by low-dose gamma
radiation. Radiat Res 1998;149:517-20.
132. Barquinero JF, Barrios L, Caballin MR, et al. Occupational exposure to radiation induces an adaptive response in human lymphocytes. Int
J Radiat Biol 1995;67:187-91.
131
133. Monsieurs MA, Thierens HM, Vral AM, et al. Adaptive response in patients treated with I. J Nucl Med 2000;41:17-22.
134. Grdina DJ, Murley JS, Miller RC, et al. A survivin-associated adaptive response in radiation therapy. Cancer Res 2013;73:4418-28.
135. Grdina DJ, Murley JS, Miller RC, et al. A manganese superoxide dismutase (SOD2)-mediated adaptive response. Radiat Res
2013;179:115-24.
136. Grdina DJ, Murley JS, Miller RC, Woloschak GE, Li JJ. NFkappaB and survivin-mediated radio-adaptive response. Radiat Res
2015;183:391-7.
137. Murley JS, Miller RC, Weichselbaum RR, Grdina DJ. TP53 mutational status and ROS effect the expression of the survivin-associated
radio-adaptive response. Radiat Res 2017;188:579-90.
138. Murley JS, Arbiser JL, Weichselbaum RR, Grdina DJ. ROS modifiers and NOX4 affect the expression of the survivin-associated radio-
adaptive response. Free Radic Biol Med 2018;123:39-52.
139. Unruhe B, Schroder E, Wunsch D, Knauer SK. An old flame never dies: Survivin in cancer and cellular senescence. Gerontology
2016;62:173-81.
140. Coleman CN, Eke I, Makinde AY, et al. Radiation-induced adaptive response: new potential for cancer treatment. Clin Cancer Res 2020;
26:5781-90.
141. Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun
2017;8:1751.
142. Gerlinger M. Targeted drugs ramp up cancer mutability. Science 2019;366:1452-3.
143. Russo M, Crisafulli G, Sogari A, et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science
2019;366:1473-80.
144. Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based
study. Lancet Oncol 2017;18:202-11.
145. Trenner A, Sartori AA. Harnessing DNA double-strand break repair for cancer treatment. Front Oncol 2019;9:1388.
146. Kirsch DG, Diehn M, Kesarwala AH, et al. The future of radiobiology. J Natl Cancer Inst 2018;110:329-40.
147. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what’s new? Future Oncol 2014;10:1215-37.
148. Toulany M. Targeting DNA double-strand break repair pathways to improve radiotherapy response. Genes 2019;10:25.
149. Mohiuddin IS, Kang MH. DNA-PK as an emerging therapeutic target in cancer. Front Oncol 2019;9:635.
150. Dong J, Ren Y, Zhang T, et al. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of
radiation-induced double strand break repair. Oncol Rep 2018;39:912-20.
151. Yang C, Wang Q, Liu X, et al. NU7441 enhances the radiosensitivity of liver cancer cells. Cell Physiol Biochem 2016;38:1897-905.
152. Sunada S, Kanai H, Lee Y, et al. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect
on double strand break repair. Cancer Sci 2016;107:1250-5.
153. Timme CR, Rath BH, O’Neill JW, Camphausen K, Tofilon PJ. The DNA-PK inhibitor VX-984 enhances the radiosensitivity of
glioblastoma cells grown in vitro and as orthotopic xenografts. Mol Cancer Ther 2018;17:1207-16.
154. Willoughby CE, Jiang Y, Thomas HD, et al. Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and
chemotherapy. J Clin Invest 2020;130:258-71.
155. Smith MC, Mader MM, Cook JA, et al. Characterization of LY3023414, a vovel PI3K/mTOR dual inhibitor eliciting transient target
modulation to impede tumor growth. Mol Cancer Ther 2016;15:2344-56.
156. Tsuji T, Sapinoso LM, Tran T, et al. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and
selectively inhibits ATM-deficient cell growth in vitro. Oncotarget 2017;8:74688-702.
157. Lindquist KE, Cran JD, Kordic K, et al. Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated
prodrug targeting DNA-dependent protein kinase. Tumour Microenv Ther 2013;1:46-55.
158. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK
activity. Radiother Oncol 2005;76:157-61.
159. Joseph K, Alkaabi K, Warkentin H, et al. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous
squamous cell carcinoma. J Med Imaging Radiat Oncol 2019;63:257-63.
160. Qi Y, Lang J, Zhu X, et al. Down-regulation of the radiation-induced pEGFRThr654 mediated activation of DNA-PK by Cetuximab in
cervical cancer cells RSC Adv 2020;10:1132-41.